BCIQ Profiles

Company Profile Report
1111 covid roundup qt
BioCentury & Getty Images

Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

Plus Vir mAb entering Phase III in preventative, hospitalized settings; and SPARK goes for temporary passive immunity via nasal drops

Nov 12, 2020 | 1:41 AM GMT

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna and NIH’s mRNA-1273 stacks up is imminent.

Antibody countermeasures are also progressing, with Vir gearing up to begin Phase III trials of its lead antiviral mAb in new treatment settings

Read the full 1112 word article

How to gain access

Continue reading with a
two-week free trial.